| scholarly article | Q13442814 |
| P50 | author | Hayden T Ravert | Q88028695 |
| Robert F Dannals | Q88679147 | ||
| Dean F Wong | Q102071157 | ||
| Bengt Långström | Q5969279 | ||
| P2093 | author name string | Links JM | |
| Burns HD | |||
| Kuhar MJ | |||
| Frost JJ | |||
| Wagner HN Jr | |||
| Lukas SE | |||
| Rosenbloom SB | |||
| Duelfer T | |||
| Kramer AV | |||
| P433 | issue | 4617 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dopamine | Q170304 |
| P304 | page(s) | 1264-1266 | |
| P577 | publication date | 1983-09-01 | |
| P1433 | published in | Science | Q192864 |
| P1476 | title | Imaging dopamine receptors in the human brain by positron tomography | |
| P478 | volume | 221 |
| Q64762152 | Q64762152 |
| Q70141446 | "Neuro-nuclear medicine" 1990: what are the prospects? |
| Q46569974 | 11C-NMSP/ 18F-FDG microPET to monitor neural stem cell transplantation in a rat model of traumatic brain injury |
| Q48336587 | 123I-MSP and F[11C]MSP: new selective 5-HT2A receptor radiopharmaceuticals for in vivo studies of neuronal 5-HT2 serotonin receptors. Synthesis, in vitro binding study with unlabelled analogues and preliminary in vivo evaluation in mice |
| Q42455246 | 123I-beta-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia |
| Q93527485 | 3-(2'-[18F]fluoroethyl)spiperone: in vivo biochemical and kinetic characterization in rodents, nonhuman primates, and humans |
| Q34192729 | 5-HT radioligands for human brain imaging with PET and SPECT |
| Q41664217 | 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone |
| Q48621818 | 76Br-bromospiroperidol: A new tool for quantitative in-vivo imaging of neuroleptic receptors |
| Q67907191 | A Comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides. Preparation and in vitro dopamine D-2 receptor binding |
| Q28834148 | A Functional Approach to Deconvolve Dynamic Neuroimaging Data |
| Q93527495 | A double-injection technique for in vivo measurement of dopamine D2-receptor density in monkeys with 3-(2'-[18F]fluoroethyl)spiperone and dynamic positron emission tomography |
| Q57946629 | A molecular orbital study on the conformational properties of dopamine [1,2-benzenediol-4(2-aminoethyl)]and dopamine cation |
| Q50466636 | A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism (Niccolini and Politis, 2016) : Reply to Jean-Claude Baron Letter to Editor. |
| Q48568559 | Absorbed fractions for dose calculations of neuroreceptor PET studies |
| Q31033082 | Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia |
| Q38728909 | Advances in nuclear imaging |
| Q70379864 | An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET |
| Q37818511 | Antipsychotic occupancy of dopamine receptors in schizophrenia |
| Q26865012 | Application of cross-species PET imaging to assess neurotransmitter release in brain |
| Q33726283 | Assays for noninvasive imaging of reporter gene expression |
| Q44671836 | Attempts to visualize nicotinic receptors in the brain of monkey and man by positron emission tomography |
| Q40172916 | Biomedical Aging Research in 1983: Some Highlights |
| Q48236658 | Brain glucose metabolism in children with the autistic syndrome: positron tomography analysis |
| Q36381172 | Caffeine improves left hemisphere processing of positive words |
| Q48408268 | Characteristics of specific in vivo labeling of neuroleptic binding sites with 3-N-[11C]methylspiperone |
| Q72584414 | Characterization of [3H]nemonapride binding to mouse brain dopamine D2 receptors assessed in vivo and ex vivo for metabolic modeling in PET studies |
| Q40473365 | Chemical brain anatomy in schizophrenia |
| Q33754464 | Clinical translation of neuroimaging research in mood disorders. |
| Q40403490 | Coincidence planar imaging for dynamic [18F]FDG uptake in nude mice with tumors and inflammation: correlated with histopathology and micro-autoradiography |
| Q45146890 | Comparison of [11C]diprenorphine and [11C]carfentanil binding to opiate receptors in humans by positron emission tomography |
| Q48519346 | Comparison of three 18F-labeled butyrophenone neuroleptic drugs in the baboon using positron emission tomography |
| Q68817233 | Concerning strategies for in vivo measurement of receptor binding using positron emission tomography |
| Q68834706 | Concerning strategies for in vivo measurement of receptor binding using positron emission tomography. II |
| Q43078340 | Convenient synthesis of 18F-radiolabeled R-(-)-N-n-propyl-2-(3-fluoropropanoxy-11-hydroxynoraporphine |
| Q46013929 | Cue-induced dopamine release predicts cocaine preference: positron emission tomography studies in freely moving rodents. |
| Q37989079 | Current and future radiopharmaceuticals for brain imaging with single photon emission computed tomography |
| Q35826639 | Cyclotrons and positron emission tomography radiopharmaceuticals for clinical imaging |
| Q41277818 | D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics |
| Q45378546 | Definition of the in-vivo accumulation of [3H]spiperone in brain using haloperidol and sulpiride to determine functional dopamine receptor occupation |
| Q73850496 | Delivery of radioligands for positron emission tomography (PET) in the central nervous system |
| Q30352651 | Designing a compact high performance brain PET scanner-simulation study |
| Q37572288 | Detection and quantification of opiate receptors in man by positron emission tomography. Potential applications to the study of pain |
| Q73482954 | Determination of unchanged [18F]dopamine in human and non-human primate plasma during positron emission tomography studies: a new solid-phase extraction method comparable to radio-thin-layer chromatography analysis |
| Q38244707 | Development of (18)F-labeled radiotracers for neuroreceptor imaging with positron emission tomography |
| Q43715446 | Development of Tc-99m labeled tropanes: TRODAT-1, as a dopamine transporter imaging agent |
| Q68310979 | Difference in in vivo receptor binding between [3 H]N-methylspiperone and [3 H]raclopride in reserpine-treated mouse brain |
| Q45292482 | Dopamine D2 Receptor Imaging with SPECT: Studies in Different Neuropsychiatric Disorders |
| Q45291180 | Dopamine D2 receptor SPECT imaging: basic in vivo characteristics and clinical applications of 123I-IBZM in humans |
| Q48683841 | Drug and Neurotransmitter Receptors in the Brain |
| Q34256020 | Effects of Age on Dopamine and Serotonin Receptors Measured by Positron Tomography in the Living Human Brain |
| Q30577260 | Effects of chronic treatment with typical and atypical antipsychotic drugs on the rat striatum |
| Q38346296 | Effects of long-term administration of antidepressants and neuroleptics on receptors in the central nervous system |
| Q40202445 | Effects of point spread function-based image reconstruction on neuroreceptor binding in positron emission tomography study with [(11)C]FLB 457. |
| Q47775208 | Effects of the GABAergic system on in vivo binding of [3H]N-methylspiperone |
| Q58120574 | Engineering molecular imaging strategies for regenerative medicine |
| Q39656985 | Estimating the effect of endogenous dopamine on baseline [(11) C]-(+)-PHNO binding in the human brain |
| Q48420914 | Evaluation of 75Br-labelled butyrophenone neuroleptics for imaging cerebral dopaminergic receptor areas using positron emission tomography |
| Q48453568 | First-pass cerebral extraction of benzamide-derivative radiotracers for SPECT. |
| Q48630419 | Fractal analysis of striatal dopamine re-uptake sites |
| Q59858574 | From Matrices to Knowledge: Using Semantic Networks to Annotate the Connectome. |
| Q48732113 | Frontotemporoparietal asymmetry and lack of illness awareness in schizophrenia |
| Q34255946 | Fundamentals of positron emission tomography and applications in preclinical drug development |
| Q48383874 | Hemispheric differences in stop task performance |
| Q37615648 | How to design PET experiments to study neurochemistry: application to alcoholism |
| Q70059150 | Human dopamine receptor subtypes--in vitro binding analysis using 3H-SCH 23390 and 3H-raclopride |
| Q48666795 | Imaging CNS Receptors: The Dopaminergic System |
| Q30807356 | Imaging methods for evaluating brain function in man. |
| Q40454686 | Imaging of pituitary tumours. |
| Q33867444 | Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review |
| Q38004437 | Imaging the serotonergic system by positron emission tomography |
| Q70232775 | Improved synthesis and low-temperature autoradiographic evaluation of 18F-n-fluoropropane as a myelin tracer for positron emission tomography |
| Q33275232 | In vitro imaging techniques in neurodegenerative diseases |
| Q44731935 | In vitro pharmacological profile of 3-N-(2-fluoroethyl)spiperone |
| Q60683358 | In vivo biodistribution of [N-11C-methyl]KF 17837 using 3-D-PET: evaluation as a ligand for the study of adenosine A2A receptors |
| Q48534724 | In vivo evaluation of [123I]-8-[4-[2-(5-iodothienyl)]-4-oxobutyl]-3-methyl-1-phenyl-1,3 ,8-tri azaspiro[4.5]decan-4-one as a potential dopamine D2 receptor radioligand for SPECT. |
| Q69727972 | In vivo labeling of dopamine receptors: light microscopic localization at the cellular level by means of dipping autoradiography with the agonist (3H)N-n-propylnorapomorphine |
| Q69298824 | In vivo labelling of pituitary dopamine D-2 receptors in the male rat using [3H]-raclopride |
| Q39485814 | In vivo measurement of dopamine receptors in human brain by positron emission tomography. Age and sex differences |
| Q33852953 | In vivo monitoring of drugs using radiotracer techniques |
| Q42513051 | Initial clinical experiences with dopamine D2 receptor imaging by means of 2'-iodospiperone and single-photon emission computed tomography |
| Q48733775 | Initial experience with SPECT examinations using [123I]IBZM as a D2-dopamine receptor antagonist in Parkinson's disease |
| Q57144951 | International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature |
| Q37106126 | Investigating the dopaminergic synapse in vivo. II. Molecular imaging studies in small laboratory animals |
| Q44336021 | Kinetic Analysis of Transport and Opioid Receptor Binding of [3H](−)-Cyclofoxy in Rat Brain in vivo: Implications for Human Studies |
| Q48870576 | Kinetic analysis of 3-quinuclidinyl 4-[125I]iodobenzilate transport and specific binding to muscarinic acetylcholine receptor in rat brain in vivo: implications for human studies |
| Q93519872 | Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET--a comparison to the equilibrium analysis |
| Q48628005 | Kinetic analysis of central [76Br]bromolisuride binding to dopamine D2 receptors studied by PET. |
| Q48263640 | Kinetic modeling of receptor-ligand binding applied to positron emission tomographic studies with neuroleptic tracers |
| Q48681896 | Kinetics of dopamine and noradrenaline transport in synaptosomes from cerebellum, striatum and frontal cortex of normal and reeler mice |
| Q48125506 | Left hemispheric predominance of nigrostriatal dysfunction in Parkinson's disease |
| Q44426141 | Linear regression with spatial constraint to generate parametric images of ligand-receptor dynamic PET studies with a simplified reference tissue model |
| Q48299393 | Localization of D-2 dopamine receptors to intrinsic striatal neurones by quantitative autoradiography |
| Q34317483 | Localization of the mRNA for the dopamine D2 receptor in the rat brain by in situ hybridization histochemistry |
| Q48361745 | Loss of striatal [76Br]bromospiperone binding sites demonstrated by positron tomography in progressive supranuclear palsy |
| Q30714273 | MR atlas of the baboon brain for functional neuroimaging. |
| Q34542568 | Major Phenolics in Apple and Their Contribution to the Total Antioxidant Capacity |
| Q41537479 | Major psychosis and dopamine: controversial features and some suggestions |
| Q28201691 | Mapping brain asymmetry |
| Q36083469 | Mapping neuroreceptors at work: on the definition and interpretation of binding potentials after 20 years of progress |
| Q48517450 | Masahiro Iio Memorial Lecture |
| Q34454591 | Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. |
| Q48867768 | Milestones |
| Q46248912 | Models for in vivo kinetic interactions of dopamine D2-neuroreceptors and 3-(2'-[18F]fluoroethyl)spiperone examined with positron emission tomography |
| Q35692925 | Molecular imaging of the brain: a historical perspective |
| Q38212402 | Molecular neuroimaging: the basics |
| Q51753002 | Multicompartmental analysis of [11C]-carfentanil binding to opiate receptors in humans measured by positron emission tomography. |
| Q48827053 | NCQ 298, a new selective iodinated salicylamide ligand for the labelling of dopamine D2 receptors |
| Q30397436 | Neural correlates of the popular music phenomenon: evidence from functional MRI and PET imaging |
| Q39428804 | Neurobiological studies of transmitter systems in aging and in Alzheimer-type dementia |
| Q36599378 | Neurologic Applications of Positron Emission Tomography |
| Q30585270 | Neuropharmacology and receptor studies in the elderly |
| Q68805724 | Neuroreceptor assay with positron emission tomography: equilibrium versus dynamic approaches |
| Q48349271 | New methods in brain imaging. |
| Q35941610 | Noninvasive imaging of reporter gene expression in living subjects |
| Q43873882 | Novel mixed ligand technetium complexes as 5-HT1A receptor imaging agents |
| Q37420841 | Overview of radiopharmaceuticals for diagnosis of central nervous disorders |
| Q48255417 | PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride |
| Q36586088 | PET imaging of dopamine receptors in human basal ganglia: relevance to mental illness |
| Q48158598 | PET measurement of D2 and S2 receptor binding of 3-N-[( 2'-18F]fluoroethyl)spiperone in baboon brain |
| Q40846516 | PET radiopharmaceuticals: state-of-the-art and future prospects |
| Q38223456 | PET scanning |
| Q68427183 | PET studies of dopamine receptor distribution using [18F]fluoroethylspiperone: findings in disorders related to the dopaminergic system |
| Q48118527 | PET studies of the uptake of (S)- and (R)-[11C]nicotine in the human brain: difficulties in visualizing specific receptor binding in vivo |
| Q39519023 | Pain and opiate receptors: considerations for the design of positron emission tomography studies |
| Q35825721 | Paradoxical effect of dopamine medication on cognition in Parkinson's disease: relationship to side of motor onset |
| Q47392942 | Partial-volume correction increases estimated dopamine D2-like receptor binding potential and reduces adult age differences. |
| Q49160683 | Pharmacokinetic analysis of plasma curves obtained after i.v. injection of the PET radioligand [11C] raclopride provides a likely explanation for rapid radioligand metabolism |
| Q34725750 | Pharmacokinetic imaging: a noninvasive method for determining drug distribution and action |
| Q36465585 | Physiological changes due to age. Pharmacodynamic changes of drug action and implications for therapy |
| Q57004543 | Positron Emission Tomography in Psychopharmacology |
| Q72601802 | Positron emission tomography |
| Q35692947 | Positron emission tomography imaging of the aging brain |
| Q39613753 | Positron emission tomography in movement disorders |
| Q48486242 | Positron emission tomography in schizophrenic patients with and without neuroleptic medication |
| Q38176164 | Positron emission tomography molecular imaging in late-life depression |
| Q33695778 | Positron emission tomography neuroreceptor imaging as a tool in drug discovery, research and development |
| Q38166974 | Positron emission tomography radioligands for the opioid system |
| Q36503237 | Positron emission tomography studies of brain receptors |
| Q48854255 | Positron emission tomography studies of neurotransmitter systems |
| Q67906240 | Positron emission tomography with (18F)methylspiperone demonstrates D2 dopamine receptor binding differences of clozapine and haloperidol |
| Q48427377 | Positron emission tomography: a technology assessment |
| Q48645057 | Pre-synaptic and post-synaptic dopaminergic system in human brain |
| Q51720558 | Probing the human brain with a simple positron detection system. |
| Q48466030 | Production of fluorine-18 labeled (3-N-methyl)benperidol for PET investigation of cerebral dopaminergic receptor binding |
| Q48487572 | Progressive supranuclear palsy: loss of striatal dopamine receptors demonstrated in vivo by positron tomography |
| Q40351665 | Psychiatry: positron emission tomography in psychiatric disorders. |
| Q48363610 | Quantification of Neuroreceptors in the living human brain. II. Inhibition studies of receptor density and affinity |
| Q41874977 | Quantification of neuroreceptors in the living human brain. I. Irreversible binding of ligands |
| Q48417560 | Quantitative imaging of neuroreceptors in the living human brain |
| Q38166968 | Radioligands for the dopamine receptor subtypes |
| Q40566753 | Radiopharmaceuticals for brain imaging |
| Q36489749 | Radiotracers for functional brain imaging |
| Q27014737 | Recent methods for measuring dopamine D3 receptor occupancy in vivo: importance for drug development |
| Q48412556 | Receptor binding of N-(methyl-11C) clozapine in the brain of rhesus monkey studied by positron emission tomography (PET). |
| Q35237793 | Receptor localization in the human hypothalamus |
| Q45862535 | Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals |
| Q39545692 | Rett syndrome: review and discussion of current diagnostic criteria |
| Q35976670 | Scintigraphic evaluation of functional hepatic mass in patients with advanced breast cancer |
| Q67915571 | Sequential enzymatic synthesis and biodistribution of radiolabelled inositol and inositol analogs |
| Q34305236 | Serotonin 5HT2 receptor imaging in the human brain using positron emission tomography and a new radioligand, [18F]altanserin: results in young normal controls |
| Q48152915 | Stereoselective binding of 11C-raclopride in living human brain--a search for extrastriatal central D2-dopamine receptors by PET. |
| Q48361734 | Strategies for in vivo measurement of receptor binding using positron emission tomography |
| Q93520402 | Striatal and frontal cortex binding of 11-C-labelled clozapine visualized by positron emission tomography (PET) in drug-free schizophrenics and healthy volunteers |
| Q37645218 | Studies of central nervous system disorders with single photon emission computed tomography and positron emission tomography: evolution over the past 2 decades |
| Q37690625 | Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography |
| Q48338332 | Symposium on imaging research in alcoholism. Introduction to the symposium |
| Q47992542 | Synthesis and evaluation of 11C-labeled nonpeptide antagonists for cholecystokinin receptors: [11C]L-365,260 and [11C]L-365,346. |
| Q33292462 | Synthesis of two potential NK1-receptor ligands using [1-11C]ethyl iodide and [1-11C]propyl iodide and initial PET-imaging |
| Q38984519 | Tactics for preclinical validation of receptor-binding radiotracers |
| Q36805793 | The Effects of Methylphenidate on Resting-State Functional Connectivity of the Basal Nucleus of Meynert, Locus Coeruleus, and Ventral Tegmental Area in Healthy Adults. |
| Q42577730 | The contribution of medical physics to nuclear medicine: a physician's perspective |
| Q27026331 | The development, past achievements, and future directions of brain PET |
| Q44351067 | The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats |
| Q41676775 | The role of positron emission tomography in pharmacokinetic analysis |
| Q73402430 | Three-dimensional visualization and quantification of the benzodiazepine receptor population within a living human brain using PET and MRI |
| Q36379273 | Tracers for metabolic imaging of brain and heart. Radiochemistry and radiopharmacology |
| Q39750049 | Two syndromes in schizophrenia and the viral hypothesis |
| Q37003212 | What has PET told us about Parkinson's disease? |
| Q37893938 | Where have we got to with neuroreceptor mapping of the human brain? |
| Q73340072 | [11C]-methyl 4-[(3,4-dichlorophenyl)acetyl]-3-[(1-pyrrolidinyl)-methyl]-1- piperazinecarboxylate ([11C]GR89696): synthesis and in vivo binding to kappa opiate receptors |
| Q58803948 | [C]SCH23390 binding to the D-dopamine receptor in the human brain-a comparison of manual and automated methods for image analysis |
| Q53666795 | [PET in neurology and psychiatry. II] |
Search more.